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Abstract: Introduction: Human Papilloma Virus (HPV) has many different epidemiological, social and political aspects.
The aim of this study was to determine the research priorities according to the necessary aspects of HPV in
Iran. Material and Methods: The national and international databases were searched to obtain the published
articles regarding HPV in Iran. All Epidemiologic studies were included in this review to assess research priori-
ties. Results: Of 148 studies involving 14,661 participants, the most studies were conducted in Tehran (44.75%)
province. Measuring prevalence of HPV (n=63, 42.5%), diagnosis of HPV by molecular techniques (n=52, 35.1%),
Knowledge, Attitude and Practice studies (KAP) (n=13, 8.7%), vaccine efficacy (n=8, 5.4%), cost and cost effec-
tiveness analysis (n=4, 2.7%), co-infection of HPV and sexually transmitted diseases (n=5, 3.3%) were the fre-
quent aims of the included studies. Sixty percent (n=57) of the studies were conducted in clinical patients in-
cluding patients with cervical cancer (n=30, 52.6%), patients with prostate cancer/Benign Prostate Hyperplasia
(n=6, 10.5%), and patients with Esophageal carcinoma (n=5, 8.7%). Conclusion: According to our results, the
high-risk groups such as female sex workers, injecting drug users and prisoners are in priority for research in the
field of HPV. Despite ample epidemiologic studies on prevalence and association of HPV with specific cancers,
evidence towards effectiveness and cost-benefits of HPV vaccination is required to prevent the infection and its
complicated clinical consequences.
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1. Introduction
Human papilloma virus (HPV) is a Sexually Transmitted In-
fections (STIs) among young and sexually active people that
spread through sexual contact (1). Previous studies have
demonstrated that highly carcinogen genotypes of HPV are
the major cause of cervical cancer. 118 types of HPVs have
been detected according to their oncogenic and phylogenetic
positions. About 40 HPV viral types observed in the geni-
tal tract which belonged to the Alpha papillomavirus genus
(2). Also, genital HPV types have been subdivided into low-
risk and high-risk types. High-risk types including subtype
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16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,66 and low-risk
types are subtype 6 and 11. It is worth noting that HPV-16 is
the most prevalent subtype throughout the world followed by
HPV18, 45, 31 and 33 subtypes (3). Getting infected by high-
risk HPV types is considered a higher risk for cervical cancer
development than infection by low-risk HPV types. Imple-
mentation of screening programs have reduced the mortal-
ity and morbidity of HPV disease (4). HPV infection has dif-
ferent aspects from molecular, epidemiological, social and
economic aspects. While we anticipate available scientific
knowledge of these aspects, there is limited research infor-
mation on many of these areas. On another perspective,
conducting research requires specialist human, financial re-
sources and time. Therefore, determining research priorities
would help us to assign the resources in the required areas
HPV and therefore, would contribute to a proper resource
allocation. The aim of this study was to determine the epi-
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demiologic research priorities according to the most impor-
tant aspects of Human Papilloma-Virus Infection (HPV infec-
tion) in Iran.
2. Methods
2.1. Description of studies
The major national and international electronic databases
were searched to obtain published re-search in the field of
HPV in Iran with the following keywords: HPV, Human Papil-
loma Virus, and Iran. The international databases searched
included, Medline (Jan 1950 to December 2019); Scopus
(Jan 1973 to December 2019) and Ovid (Jan 1860 to Decem-
ber 2019). The national databases searched, included Sci-
entific Information Database, MagIran and IranMedex up
to December 2019. Inclusion criteria was defined as all
studies investigating Human Papilloma Virus (HPV) with-
out any language restriction. Exclusion criteria was de-
fined as those investigating Non-Iranian population, or those
whose first or corresponding author was affiliated to institu-
tions/organizations outside Iran. We retrieved 180 studies in-
cluding 133 references from international databases and 47
from the national databases (Fig. 1). Of these, 10 were ex-
cluded because of duplication, 14 were excluded because not
related to the Iranian population. At the final phase, 8 studies
were excluded including case-reports/series, editorials and
letter to editors.
3. Results
We assessed 148 epidemiologic studies that conducted in
Iran involved 14,661 participants. The first and last studies
in the field of HPV, which included in this study, were pub-
lished in 2002 and 2019, respectively. The trend of published
studies within this period was increasing. The highest pro-
portion of articles (22%) were published in 2011 and 2018. All
of included studies were in English language.
3.1. Location
Regarding the location of study, 44.75% of the studies were
conducted in Tehran province, which related to Tehran,
Shahid Beheshti and Iran universities of Medical Sciences.
Mazandaran and Isfahan universities of Medical Sciences
had second and third ranks of published papers (12.9% and
9.5%, respectively).
None of the included studies was related to the catchment
areas of universities in Arak, Ardebil, Bandar Abbas, Ghom,
Ghazvin, Gonabad, Hamadan, Ilam, Kashan, Jahrom, Jiroft,
Lorestan, Rafsanjan, Shahrekord, Sari, Sabzevar, Semnan,
Shahroud, Zanjan, and Yazd. The lowest proportion of pub-
lished papers belonged to universities located in border-
line provinces such as North Khorasan, Khorasan Razavi,
Boushehr, West Azerbaijan, and Zabol.
3.2. Type of studies
During 2002 to 2019, cross-sectional studies consisted of
42.5% of conducted studies in Iran. Molecular studies and
review/systematic review articles were the second and third
highest proportion of published papers (35.1% and 13.5%, re-
spectively).
3.3. Study subjects
Forty percent (n=39) of the included studies were con-
ducted in general population while the rest (n=57, 60%)
were conducted in clinical patients including patients with
cervical cancer (n=30, 52.6%), patients with prostate can-
cer/Benign Prostate Hyperplasia (n=6, 10.5%), and patients
with Esophageal carcinoma (n=5, 8.7%). Sporadic studies
also were conducted on other clinical diseases such as pa-
tients warts Anal-genital warts (n=4, 7%), Infertile patients
(n=2, 3.5%), Squamous cell carcinoma: eye conjunctive (n=1,
1.7%), Gastric carcinoma (n=1, 1.7%), Female Sex Workers
(n=1, 1.7%), HIV positive cases (n=1, 1.7%), Lung cancer pa-
tients (n=1, 1.7%), Head & neck cancer (n=1, 1.7%), and illicit
drug users (n=1, 1.7%).
3.4. Aim of the study
Various research objectives had been pursued by the au-
thors in the field of HPV, which included Prevalence of HPV
(n=63, 42.5%), Diagnosis of HPV by Molecular techniques
(n=52, 35.1%), Knowledge, Attitude and Practice (KAP) stud-
ies (n=13, 8.7%), Vaccine efficacy (n=8, 5.4%), Cost and cost
effectiveness analysis (n=4, 2.7%), Co-infection of HPV and
STIs (n=5, 3.3%). On the other hand, we found no study
on the effectiveness of education programs on prevention of
HPV, issues related to survival and mortality of HPV-related
cancers, measuring quality of life in HPV patients, studies on
stigma and prejudice among HPV patients, and qualitative
studies on experience, perception and behavior of HPV pa-
tients.
3.5. Recommendation for further studies
Based on the recommendations for more studies, 53% (n=33)
authors of cross-sectional studies suggested more studies in
the field of HPV. Further studies were also recommended in
all the case-control studies (n=8, 100%), and experimental
studies (n=2, 100%) (Table 1).
4. Discussion
According to our results, the most published studies were
conducted in Tehran province consisting of Tehran, Shahid
Beheshti and Iran Universities of Medical Sciences. The re-
maining studies were mainly belonged to other provinces
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jmp.iums.ac.ir
3 Men’s Health Journal. 2019; 3(1): e20
such as Mazandaran and Isfahan. Compare to the other parts
of the country, population density of Tehran Province is sub-
stantially higher, which justifies the higher proportion of re-
search works in Tehran Province. Consequently, the catch-
ment area covered by the universities of medical sciences lo-
cated in Tehran city is higher compared to other universities
across the country.
We found that more than one-third of the research papers
in the field of HPV had conducted in general population
in Iran while more than half of these papers are in cross-
sectional design. Epidemiologic studies on general popula-
tion are mainly conducted to estimate the prevalence of HPV
serotypes, in other words, estimates of natural exposure to
types of HPV. Along with estimated prevalence of HPV expo-
sure, cross-sectional studies might provide additional infor-
mation such as age pattern of infection, geographic variation
and high priority groups for HPV screening. This type of in-
formation, as a preliminary step, is useful toward planning
for HPV vaccination and implementation of proper preven-
tive programs for HPV infection and related clinical disor-
ders(5).
On the other hand, limited studies have conducted on groups
of patients, amongst them more than half of the studies con-
ducted in cervical cancer patients. Certain genotypes of Hu-
man papillomaviruses (HPVs) are found to be involved in hu-
man malignancies. Infection by these specific types of HPV,
particularly HPV16 and 18, is reported to be responsible in
development of HPV-related cancers. The most HPV-related
cancers are associated to infection by high-risk types includ-
ing 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 and 73(6,
7). After the initial infection, tumors progress in the epithe-
lia. Persistent infection with expression of some viral genes,
particularly E6 and E7 is needed for development of invasive
cancer. However, most HPV infections have a benign out-
come because nearly half of them clear within 6 months and
up to 2 years the majority of cases clear from infection, but
those that persist can progress to cancer(8). On public health
perspective, the idea of biologic origin of cancers which led
to the discovery of HPV as an important biologic cause of
many malignancies is important. Due to the presence of an
effective vaccine for HPV, the prevention of HPV-related can-
cer has become more promising (9, 10) .
One of the most important HPV-related malignancies is cer-
vical cancer. Cervical cancer is the third most common gy-
necologic cancer globally and the eleventh common cancer
among Iranian women(11). Persistent infection with high
risk human papilloma virus types in the development of cer-
vical intraepithelial neoplasia and cervical cancer has been
demonstrated for many years (12). However, epidemiologi-
cal information is necessary to pave the way for better un-
derstanding the population-level mechanism and evaluating
the risk of developing neoplasia in women who are found to
be infected with certain types of HPVs in each population.
We found that only one study has reported the prevalence of
HPV in breast cancer patients while amongst the molecular
studies, 15 (28%) were performed on breast tissues. Breast
cancer is reported to be the most frequent malignancy in
women globally. A number of risk factors have been asso-
ciated with breast cancer, including age, obesity and famil-
ial history while their minor attribution to pathogenesis of
breast cancer has highlighted the need to recognize other
factors. The link between HPV and etiology of breast can-
cer dates back to 1992. The prevalence of HPV infection
among women with breast cancer have been reported up to
86.2% (13). It was found that the pathogenicity of HPV on
breast cancer depends on HPV genotypes. Therefore, HPV
16, HPV18 and HPV33, which consists of the high risk types
are known for 70% of breast cancer cases worldwide (14).
Other studies in Iran have investigated the role of HPV in
other morbidities such as STDs. Sexually transmitted infec-
tions (STIs) and Sexually Transmitted Diseases (STDs) are
major public health concerns worldwide. Youth and high-
risk populations have usually been considered to be at an
elevated risk for getting STIs(15). This is of particular con-
cern, as untreated STIs may result in infertility, ectopic preg-
nancy, preterm labor, fetal and neonatal death, cancer, and
increased risk for HIV acquisition and transmission(16).
Our results showed that the proportion of studies that con-
ducted on drug addicts, female sex workers, or patients with
HIV was low. These groups are hidden, hard-to-reach in Iran.
Therefore, more studies should be done in these groups(17).
Treatment effectiveness in patients depends to complete ad-
herence in patients who getting HPV vaccination. HPV vacci-
nation is essential to prevention of HPV and decrease in the
risk of its transmission. Despite presence of an effective vac-
cine, limited studies on the effectiveness and cost-benefits
of HPV vaccines are conducted in Iran. Only 8 studies (5.4%
of all studies) are conducted with the aim to provide enough
evidence for HPV vaccination. Given that the quadrivalent
Gardasil vaccine is not yet apart of the Iranian national im-
munization program, cost-effectiveness analysis are highly
warranted for new vaccines to determine whether its impact
will be great enough to economically benefit the country (18).
Better management and treatment of HPV depends heavily
on having an overview of knowledge and attitude toward HPV
infection in general population. Several studies have indi-
cated that despite the high prevalence of HPV, even among
informed people, there is lack of knowledge or false percep-
tions towards HPV(19). There is evidence that acceptance of
HPV vaccination is increased when parents or young women
are well informed about its risks and benefits (20). So, knowl-
edge and attitude toward HPV infection and HPV vaccines
will greatly influence the success of an immunization pro-
gram against cervical cancer (20). Our study showed that
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nearly 10% of all studies aimed to measure Knowledge, At-
titude, and Practice (KAP) regarding HPV prevention. Also,
systematic review and meta-analysis have performed in this
field. Systematic review and a meta-analysis that conducted
on KAP studies in the field of HPV showed that knowledge
and attitude of Iranian individual towards prevention of HPV
is not satisfactory(21).
More studies in people who living with HPV is necessary to
identify factors that could affect prevention of HPV among
Iranian patients. Studies that related to HPV patients sug-
gested that more research must perform in this people. These
findings emphasize on preventive studies.
Qualitative investigations related with experience, percep-
tion and behavior of HPV patients had a low proportion of
conducted studies in the field of HPV in Iran. Some as-
pects of life among people with HPV are better surveyed us-
ing qualitative investigations. On the other hand, we pro-
pose that qualitative research is useful for evaluation some
dimensions of life among people who are living with HPV.
Reviews/Systematic reviews and meta-analysis were studies
with relatively high proportion. In the category of observa-
tional studies, there has been no prospective cohort study on
HPV outcomes and complications. Additionally, clinical and
field trails, especially in forms of educational interventions,
are recommended for evaluation of new treatment or thera-
peutic options for HPV prevention and control. Epidemiolo-
gists and biostatisticians were as the important members of
investigation teams for evaluation methodological aspects of
these studies.
The recommendations that studies have mentioned for fur-
ther research include: cost-effectiveness programs for HPV
vaccination, increasing knowledge of the general population
regarding importance of HPV, the importance of HPV screen-
ing for cervical percutaneous lesions, sexual health educa-
tion specifically for adolescents, the need to diagnose HPV
in young females, and the need to screen for HPV in males
to prevent prostate cancers. Our results indicated that High
risk behavior/ High risk group and co-infection of HPV are
the investigation priorities in Iran.
5. Conclusion
According to our results, the high-risk groups such as female
sex workers, injecting drug users and prisoners are in priority
for research in the field of HPV. Despite ample epidemiologic
studies on prevalence and association of HPV with specific
cancers, evidence towards effectiveness and cost-benefits of
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Figure 1: Flowchart of the included studies to determine research priorities in the field of HPV.
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Table 1: Distribution of studies according to study type, study population, aim and recommendation for further studies in Iran.
Variable Freq. Percent Recommendation for further studies
No N (%) Yes N (%)
Cross-sectional 63 42.5 30 (47) 33 (53)
Case-control 8 5.4 0(0) 8 (100)
Case-series 3 2.0 3 (100) 0(0)
Type of study Prospective cohort 0 0.0 - -
Retrospective cohort 0 0.0 - -
Laboratory studies 52 35.1 22 (42) 30(58)
Clinical trial 2 1.3 0 (0) 2(100)
Review/Systematic review 20 13.5 18 (90) 2 (10)
General population 39 40.0 0 (0) 39 (100)
Clinical Patients 57* 60.0 20 (35) 37 (65)
Cervical cancer 30 52.6 10 20
Prostate cancer/BPH£ 6 10.5 3 3
Esophageal carcinoma 5 8.7
Anal-genital warts 4 7.0
Patients with Oral Tumors 2 3.5 2 (100) 0 (0)
Study population Infertile patients 2 3.5
Squamous cell carcinoma: eye
conjunctive
1 1.7 0 (0) 1(100)
Gastric carcinoma 1 1.7 0(0) 1(100)
Breast cancer 1 1.7 1(100) 0(0)
Female Sex Workers (FSW) 1 1.7 1(100) 0(0)
HIV+ patients 1 1.7 1(100) 0(0)
Lung cancer 1 1.7 0(0) 1(100)
Head & neck cancer 1 1.7 0(0) 1(100)
Illicit Drug users 1 1.7 1 (100) 0(0)
Prevalence of HPV 63 42.5 60 (95.2) 3 (4.8)
Diagnosis of HPV by Molecular
techniques
52 35.1 30 (57.7) 22 (42.3)
KAPΩ study 13 8.7 3 (23) 10 (67)
Vaccine efficacy 8 5.4 2 (25) 6 (75)
Cost and cost effectiveness
analysis
4 2.7 0 (0) 4 (100)
Aim of the study Co-infection of HPV and STIs 5 3.3 1 (20) 4 (80)
High risk behavior/ High risk
group
3 2 0 (0) 3 (100)
Effectiveness of education pro-
grams
0 - - -
Survival and mortality 0 - - -
Quality of life 0 - - -
Prevention 0 - - -
Stigma and prejudice 0 - - -
Experience, perception and be-
havior of patients
0 - - -
*excluding molecular studies, £ Benign Prostate Hyperplasia, ΩKnowledge, Attitude, and Practice study.
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